Aurora Cannabis

Aurora Cannabis is buying 100% of Internode Pharma and HAP Pharma for £2.1 million in cash, gaining a licensed import and distribution hub and a virtual pharmacy in Birmingham. The acquisition gives Aurora direct control of the medical cannabis supply chain in the UK and targets growth in the British market. Payment is subject to closing conditions; Aurora expects the deal to contribute to adjusted EBITDA over time through operational efficiencies and reduced reliance on third parties. » More on de.investing.com

Aurora Cannabis has received an unsolicited takeover offer from Curaleaf and recommends that shareholders take no action for the time being. Curaleaf’s bid values Aurora at $4.00 per share (0.3463 Curaleaf shares plus $0.75 in cash) with an upside cap of $5.00 per share. The board formed an independent special committee to review the offer with advisers and to issue a recommendation within 15 days; the offer period runs for at least 105 days until at least December 1, 2026. CEO Miguel Martin accuses Curaleaf of primarily trying to acquire Aurora’s EU‑GMP production facilities and medical platforms at a bargain price. » More on de.investing.com

Aurora Cannabis will publish results for the quarter to 30 June 2026 on 5 August 2026. Five analysts estimate EPS at an average of -0.183 CAD versus -0.270 CAD in the year‑ago quarter. Six analysts expect revenue of around 67.4 million CAD (‑31.24% year on year) and an average loss of -0.418 CAD for the current fiscal year with revenue expectations of 288.6 million CAD. » More on finanzen.net